Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme

Abstract Glioblastoma (GBM), a prevalent and malignant brain tumor, poses a challenge in surgical resection due to its invasive nature within the brain parenchyma. CDKN1A (p21, Waf-1), a cyclin-dependent kinase inhibitor, plays a pivotal role in regulating cell growth arrest, terminal differentiatio...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Wen-Yu Cheng, Chiung-Chyi Shen, Yea-Jiuen Liang, Ming-Tsang Chiao, Yi-Chin Yang, Wan-Yu Hsieh, Cheng-Hui Lin, Jun-Peng Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-09-01
coleção:	BMC Cancer
Assuntos:	Glioblastoma CDKN1A c.93C > A Bevacizumab Polymorphism PCR–RFLP
Acesso em linha:	https://doi.org/10.1186/s12885-023-11400-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!